MRC1 and neoplasm: To investigate the immune mechanisms underlying the enhanced antitumor response observed with MMR and ICB combination therapy (Figure 3), we used flow cytometry (gating strategies shown in Supplementary Figures 6-8) to analyze immune profiles of the tumor microenvironment (TME) according to the treatment schedule outlined in Figure 5A.